Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients
Diabetes Care2008Vol. 31(6), pp. 1224–1229
Citations Over TimeTop 1% of 2008 papers
Stéphane De Wit, Caroline Sabin, Rainer Weber, Signe Westring Worm, Peter Reiss, Charles Cazanave, Wafaa El‐Sadr, Antonella d’Arminio Monforte, Éric Fontas, Matthew Law, Nina Friis‐Møller, Andrew Phillips
Abstract
Stavudine and zidovudine are significantly associated with diabetes after adjustment for risk factors for diabetes and lipids. Adjustment for lipodystrophy did not modify the relationship, suggesting that the two thymidine analogs probably directly contribute to insulin resistance, potentially through mitochondrial toxicity.
Related Papers
- → Zidovudine, Didanosine, or Both as the Initial Treatment for Symptomatic HIV-Infected Children(1997)156 cited
- → Combination Therapy with ZDV + DDI Versus ZDV + DDC in Patients with Progression of HIV-Infection Under Treatment with ZDV(1996)3 cited
- → Inhibition of Human Immunodeficiency Virus Type 1 Replication In Vitro by the Bisheteroarylpiperzine Atevirdine (U-87201E) in Combination with Zidovudine or Didanosine(1993)25 cited
- → Intrathecal Immunoactivation in Patients with HIV-1 Infection is Reduced by Zidovudine but not by Didanosine(1996)8 cited
- Zidovudine plus didanosine in primary HIV-1 infection.(1997)